Precision BioSciences is a publicly traded corporate entity listed on the Nasdaq Global Market under the ticker symbol DTIL, meaning it is collectively owned by its public shareholders, institutional investors, mutual funds, and corporate insiders. It was originally founded in March 2006 by scientific co-founders Derek Jantz and Jeff Smith alongside Matt Kane, who structured its foundational genome-editing technology before taking the enterprise public via an initial public offering.